Individualizing the treatment of patients with heart failure with reduced ejection fraction depending on the clinical phenotype Case report
Article Sidebar
Published:
Dec 31, 2022
Keywords:
heart failure, clinical phenotypes, spironolactone, ivabradine
Main Article Content
Abstract
Heart failure is a serious clinical problem and it’s incidence increases with age. Patients with heart failure are a heterogeneous group in terms of basic clinical indicators, such as congestion, blood pressure, heart rate, atrial fibrillation, renal function, and electrolytes. Different clinical phenotypes of patients should lead to an individual approach to optimizing the treatment of heart failure. Aldosterone antagonists, including spironolactone, are the foundation of the treatment of patients with heart failure with reduced ejection fraction. Heart rate reduction with ivabradine is beneficial in certain patients with heart failure.
Article Details
How to Cite
Nitka , A., & Lewandowski , J. (2022). Individualizing the treatment of patients with heart failure with reduced ejection fraction depending on the clinical phenotype. Medycyna Faktow (J EBM), 15(4(57), 458-461. https://doi.org/10.24292/01.MF.0422.14
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. McDonagh TA, Metra M, Adamo M et al; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42: 3599-726.
2. Czech M, Opolski G, Zdrojewski T et al. The costs of heart failure in Poland from the public payer`s perspective. Polish programme assessing diagnostic procedures, treatment and costs in patients with heart failure in randomly selected outpatient clinics and hospitals at different levels of care: POLKARD. Kardiol Pol. 2013; 71(3): 224-32. http://doi.org/10.5603/KP.2013.0032.
3. Niewydolność serca w Polsce. Realia, koszty, sugestie poprawy sytuacji.
4. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016; 18: 891-975.
5. Rosano GMC, Moura B, Metra M et al. Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2021; 23(6): 872-81.
6. Swedberg K, Komajda M, Böhm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010; 376(9744): 875-85.
7. Charakterystyka produktu leczniczego Spironol.
8. Rosano GMC, Tamargo J, Kjeldsen KP et al. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J Cardiovasc Pharmacother. 2018; 4(3): 180-8. http://doi.org/10.1093/ehjcvp/pvy015.
9. Charakterystyka produktu leczniczego Raenom.
2. Czech M, Opolski G, Zdrojewski T et al. The costs of heart failure in Poland from the public payer`s perspective. Polish programme assessing diagnostic procedures, treatment and costs in patients with heart failure in randomly selected outpatient clinics and hospitals at different levels of care: POLKARD. Kardiol Pol. 2013; 71(3): 224-32. http://doi.org/10.5603/KP.2013.0032.
3. Niewydolność serca w Polsce. Realia, koszty, sugestie poprawy sytuacji.
4. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016; 18: 891-975.
5. Rosano GMC, Moura B, Metra M et al. Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2021; 23(6): 872-81.
6. Swedberg K, Komajda M, Böhm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010; 376(9744): 875-85.
7. Charakterystyka produktu leczniczego Spironol.
8. Rosano GMC, Tamargo J, Kjeldsen KP et al. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J Cardiovasc Pharmacother. 2018; 4(3): 180-8. http://doi.org/10.1093/ehjcvp/pvy015.
9. Charakterystyka produktu leczniczego Raenom.